Arvinas/$ARVN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Arvinas

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Ticker

$ARVN
Sector
Primary listing

Employees

430

Arvinas Metrics

BasicAdvanced
$719M
-
-$1.00
2.23
-

What the Analysts think about Arvinas

Analyst ratings (Buy, Hold, Sell) for Arvinas stock.

Bulls say / Bears say

Out-licensing vepdegestrant to a third party and putting in place cost-cutting measures, including workforce reductions and $80m–$100m in annual savings, are set to free up over $100m in yearly cash flow and enable a new $100m share buyback to boost shareholder value (Reuters)
Phase 3 trial data showed vepdegestrant extended progression-free survival to five months versus two months for AstraZeneca's Faslodex in ESR1-mutant breast cancer patients, underscoring the effectiveness of Arvinas’s PROTAC platform (Reuters)
Vepdegestrant is under FDA review with a decision expected in June, providing a near-term regulatory catalyst; analyst estimates indicate ~$576m peak sales potential by 2032 (Reuters, Reuters)
Shares of Arvinas fell 3.4% in after-hours trading following the announcement of out-licensing vepdegestrant, showing investor concerns over its growth outlook and strategy (Reuters)
Arvinas has chosen not to proceed with two other planned late-stage studies of vepdegestrant, pointing to execution risks and potential pipeline delays (Reuters)
The company has cut its workforce by a total of 48% since May (33% in May and another 15% in September), which may impact its R&D capabilities and slow its pipeline progress (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.

Arvinas Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Arvinas Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ARVN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Arvinas stock | $ARVN Share Price | Lightyear